Clinton Bybee - Net Worth and Insider Trading

Clinton Bybee Net Worth

The estimated net worth of Clinton Bybee is at least $291 Million dollars as of 2026-09-11. Clinton Bybee is the Director of Impinj Inc and owns about 1,371,152 shares of Impinj Inc (PI) stock worth over $236 Million. Clinton Bybee is also the 10% Owner of Alnylam Pharmaceuticals Inc and owns about 222,500 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $55 Million. Details can be seen in Clinton Bybee's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Clinton Bybee has not made any transactions after 2017-11-09 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Clinton Bybee

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

PI Impinj Inc

81% of holdings · $235.6M

ALNY Alnylam Pharmaceuticals Inc

19% of holdings · $55.1M

Clinton Bybee Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Clinton Bybee owns 36 companies in total, including Codiak BioSciences Inc (CDAKQ) , Metacrine Inc (MTCR) , and Impinj Inc (PI) among others .

Click here to see the complete history of Clinton Bybee’s form 4 insider trades.

Insider Ownership Summary of Clinton Bybee

Ticker	Company	Transaction Date	Type of Owner
CDAKQ	Codiak BioSciences Inc	2020-10-13	10 percent owner
MTCR	Metacrine Inc	2020-09-15	10 percent owner
PI	Impinj Inc	2017-11-09	director
		2020-02-05	10 percent owner
		2021-03-30	10 percent owner
		2019-08-08	10 percent owner
		2019-03-07	10 percent owner
		2019-06-27	10 percent owner
		2018-03-27	10 percent owner
		2019-02-22	10 percent owner
		2019-02-07	10 percent owner
		2018-11-02	10 percent owner
		2018-05-23	10 percent owner
		2018-05-02	10 percent owner
		2018-04-03	other: Former 10% owner
		2020-11-20	10 percent owner
		2016-10-11	director & 10 percent owner
		2016-05-23	10 percent owner
		2016-03-15	10 percent owner
		2015-10-30	10 percent owner
		2015-01-14	10 percent owner
		2014-06-23	10 percent owner
		2015-02-13	10 percent owner
		2014-03-17	10 percent owner
		2013-09-30	10 percent owner
		2013-06-18	10 percent owner
		2011-07-21	10 percent owner
		2004-03-10	10 percent owner
		2004-05-27	10 percent owner
		2003-11-26	10 percent owner
		2020-12-17	10 percent owner
		2021-02-03	10 percent owner
		2021-06-16	10 percent owner
		2023-09-14	10 percent owner
		2018-03-27	10 percent owner
		2024-03-27	10 percent owner

Clinton Bybee Latest Holdings Summary

Clinton Bybee currently owns a total of 2 stocks. Among these stocks, Clinton Bybee owns 1,371,152 shares of Impinj Inc (PI) as of November 9, 2017, with a value of $236 Million and a weighting of 81.05%. Clinton Bybee also owns 222,500 shares of Alnylam Pharmaceuticals Inc (ALNY) as of May 27, 2004, with a value of $55 Million and a weighting of 18.95%.

Latest Holdings of Clinton Bybee

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PI	Impinj Inc	2017-11-09	1,371,152	171.79	235,550,202
ALNY	Alnylam Pharmaceuticals Inc	2004-05-27	222,500	247.51	55,070,975

Holding Weightings of Clinton Bybee

Clinton Bybee Form 4 Trading Tracker

According to the SEC Form 4 filings, Clinton Bybee has made a total of 0 transactions in Impinj Inc (PI) over the past 5 years. The most-recent trade in Impinj Inc is the acquisition of 4,000 shares on November 9, 2017, which cost Clinton Bybee around $97,720.

According to the SEC Form 4 filings, Clinton Bybee has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 0 shares on May 27, 2004, which brought Clinton Bybee around $0.

Insider Trading History of Clinton Bybee

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Clinton Bybee Trading Performance

GuruFocus tracks the stock performance after each of Clinton Bybee's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Clinton Bybee is -51.02%. GuruFocus also compares Clinton Bybee's trading performance to market benchmark return within the same time period. The performance of stocks bought by Clinton Bybee within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Clinton Bybee's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Clinton Bybee

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-6.51
Relative Return to S&P 500(%)	-9.1

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Clinton Bybee owns.

- PI - ALNY

View PI Analysis

Clinton Bybee Ownership Network

Ownership Network List of Clinton Bybee

No Data

Ownership Network Relation of Clinton Bybee

Clinton Bybee Owned Company Details

What does Codiak BioSciences Inc do?

Who are the key executives at Codiak BioSciences Inc?

Clinton Bybee is the 10 percent owner of Codiak BioSciences Inc. Other key executives at Codiak BioSciences Inc include See Remarks Yalonda Howze , Chief Scientific Officer Sriram Sathyanarayanan , and See Remarks Nicole Barna .

Codiak BioSciences Inc (CDAKQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Codiak BioSciences Inc (CDAKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Codiak BioSciences Inc (CDAKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Codiak BioSciences Inc (CDAKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Codiak BioSciences Inc Insider Transactions

No Available Data

What does Metacrine Inc do?

Who are the key executives at Metacrine Inc?

Clinton Bybee is the 10 percent owner of Metacrine Inc. Other key executives at Metacrine Inc include Chief Business Officer Michael York , director & President & CEO Preston Klassen , and 10 percent owner Braden Michael Leonard .

Metacrine Inc (MTCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Metacrine Inc (MTCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Metacrine Inc (MTCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Metacrine Inc (MTCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Metacrine Inc Insider Transactions

No Available Data

What does Impinj Inc do?

Who are the key executives at Impinj Inc?

Clinton Bybee is the director of Impinj Inc. Other key executives at Impinj Inc include Chief Financial Officer Cary Baker , 10 percent owner Sylebra Capital Llc , and director & Chief Executive Officer Diorio Chris Ph.d. .

Impinj Inc (PI) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Impinj Inc (PI). Other recent insider transactions involving Impinj Inc (PI) include a net sale of 1,346,317 shares made by Sylebra Capital Llc , a net sale of 39,096 shares made by Diorio Chris Ph.d. , and a net sale of 1,429 shares made by Cary Baker .

In summary, during the past 3 months, insiders sold 1,429 shares of Impinj Inc (PI) in total and bought 0 shares, with a net sale of 1,429 shares. During the past 18 months, 1,387,184 shares of Impinj Inc (PI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,387,184 shares.

Impinj Inc (PI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Impinj Inc Insider Transactions

No Available Data

What does Beam Therapeutics Inc do?

Who are the key executives at Beam Therapeutics Inc?

Clinton Bybee is the 10 percent owner of Beam Therapeutics Inc. Other key executives at Beam Therapeutics Inc include Chief Medical Officer Amy Simon , director & CEO John M. Evans , and 10 percent owner & other: See Remark 1 Fmr Llc .

Beam Therapeutics Inc (BEAM) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Beam Therapeutics Inc (BEAM). Other recent insider transactions involving Beam Therapeutics Inc (BEAM) include a net sale of 260,741 shares made by John M. Evans , a net sale of 33,257 shares made by Christine Bellon , and a net sale of 55,553 shares made by Amy Simon .

In summary, during the past 3 months, insiders sold 351,900 shares of Beam Therapeutics Inc (BEAM) in total and bought 0 shares, with a net sale of 351,900 shares. During the past 18 months, 759,738 shares of Beam Therapeutics Inc (BEAM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 759,738 shares.

Beam Therapeutics Inc (BEAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Beam Therapeutics Inc Insider Transactions

No Available Data

What does Vir Biotechnology Inc do?

Who are the key executives at Vir Biotechnology Inc?

Clinton Bybee is the 10 percent owner of Vir Biotechnology Inc. Other key executives at Vir Biotechnology Inc include SVP & Chief Accounting Officer Brent Sabatini , Chief Executive Officer Backer Marianne De , and EVP and Chief Medical Officer Mark Eisner .

Vir Biotechnology Inc (VIR) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Vir Biotechnology Inc (VIR). Other recent insider transactions involving Vir Biotechnology Inc (VIR) include a net sale of 2,955,117 shares made by Softbank Vision Fund (aiv M1) L.p. , a net sale of 262,377 shares made by Vicki L Sato , and a net sale of 12,879 shares made by Brent Sabatini .

In summary, during the past 3 months, insiders sold 0 shares of Vir Biotechnology Inc (VIR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,474,355 shares of Vir Biotechnology Inc (VIR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,474,355 shares.

Vir Biotechnology Inc (VIR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vir Biotechnology Inc Insider Transactions

No Available Data

What does Denali Therapeutics Inc do?

Who are the key executives at Denali Therapeutics Inc?

Clinton Bybee is the 10 percent owner of Denali Therapeutics Inc. Other key executives at Denali Therapeutics Inc include Chief Medical Officer Peter Scott Chin , COO and Secretary Alexander O. Schuth , and director & President and CEO Ryan J. Watts .

Denali Therapeutics Inc (DNLI) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Denali Therapeutics Inc (DNLI). Other recent insider transactions involving Denali Therapeutics Inc (DNLI) include a net sale of 25,780 shares made by Alexander O. Schuth , a net sale of 530,480 shares made by Ryan J. Watts , and a net sale of 11,439 shares made by Nancy Thornberry .

In summary, during the past 3 months, insiders sold 18,718 shares of Denali Therapeutics Inc (DNLI) in total and bought 0 shares, with a net sale of 18,718 shares. During the past 18 months, 573,096 shares of Denali Therapeutics Inc (DNLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 573,096 shares.

Denali Therapeutics Inc (DNLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Denali Therapeutics Inc Insider Transactions

No Available Data

What does Syros Pharmaceuticals Inc do?

Who are the key executives at Syros Pharmaceuticals Inc?

Clinton Bybee is the 10 percent owner of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include Chief Legal & Compliance Offic Gerald E Quirk , Chief Medical Officer David Roth , and Chief Financial Officer Jason Haas .

Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syros Pharmaceuticals Inc Insider Transactions

No Available Data

What does Karuna Therapeutics Inc do?

Who are the key executives at Karuna Therapeutics Inc?

Clinton Bybee is the 10 percent owner of Karuna Therapeutics Inc. Other key executives at Karuna Therapeutics Inc include Chief Medical Officer Stephen K. Brannan , Chief Financial Officer Jason Parker Brown , and Chief Financial Officer Troy A. Ignelzi .

Karuna Therapeutics Inc (KRTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Karuna Therapeutics Inc (KRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Karuna Therapeutics Inc (KRTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Karuna Therapeutics Inc (KRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Karuna Therapeutics Inc Insider Transactions

No Available Data

What does Homology Medicines Inc do?

Who are the key executives at Homology Medicines Inc?

Clinton Bybee is the 10 percent owner of Homology Medicines Inc. Other key executives at Homology Medicines Inc include director & President & CEO Arthur Tzianabos , See Remarks Paul Alloway , and Chief Scientific Officer Albert Seymour .

Homology Medicines Inc (FIXX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Homology Medicines Inc (FIXX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Homology Medicines Inc (FIXX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Homology Medicines Inc (FIXX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Homology Medicines Inc Insider Transactions

No Available Data

What does Sienna Biopharmaceuticals Inc do?

Who are the key executives at Sienna Biopharmaceuticals Inc?

Clinton Bybee is the 10 percent owner of Sienna Biopharmaceuticals Inc. Other key executives at Sienna Biopharmaceuticals Inc include Chief Financial Officer Alexander Azoy , Chief Medical Officer Paul F. Lizzul , and director & President & CEO Iii Frederick Beddingfield .

Sienna Biopharmaceuticals Inc (SNNAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sienna Biopharmaceuticals Inc (SNNAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sienna Biopharmaceuticals Inc (SNNAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sienna Biopharmaceuticals Inc Insider Transactions

No Available Data

What does Gossamer Bio Inc do?

Who are the key executives at Gossamer Bio Inc?

Clinton Bybee is the 10 percent owner of Gossamer Bio Inc. Other key executives at Gossamer Bio Inc include Chief Medical Officer Richard Aranda , director & Executive Chairman Faheem Hasnain , and Chief Financial Officer Bryan Giraudo .

Gossamer Bio Inc (GOSS) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Gossamer Bio Inc (GOSS). Other recent insider transactions involving Gossamer Bio Inc (GOSS) include a net purchase of 26,050 shares made by Sandra Milligan ,

In summary, during the past 3 months, insiders sold 0 shares of Gossamer Bio Inc (GOSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Gossamer Bio Inc (GOSS) were sold and 26,050 shares were bought by its insiders, resulting in a net purchase of 26,050 shares.

Gossamer Bio Inc (GOSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gossamer Bio Inc Insider Transactions

No Available Data

What does Twist Bioscience Corp do?

Who are the key executives at Twist Bioscience Corp?

Clinton Bybee is the 10 percent owner of Twist Bioscience Corp. Other key executives at Twist Bioscience Corp include See Remarks Dennis Cho , Chief Accounting Officer Robert F. Werner , and VP of Human Resources Paula Green .

Twist Bioscience Corp (TWST) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Twist Bioscience Corp (TWST). Other recent insider transactions involving Twist Bioscience Corp (TWST) include a net sale of 94,261 shares made by Dennis Cho , a net sale of 416,810 shares made by Emily M. Leproust , and a net sale of 102,650 shares made by Paula Green .

In summary, during the past 3 months, insiders sold 399,795 shares of Twist Bioscience Corp (TWST) in total and bought 0 shares, with a net sale of 399,795 shares. During the past 18 months, 1,040,426 shares of Twist Bioscience Corp (TWST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,040,426 shares.

Twist Bioscience Corp (TWST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Twist Bioscience Corp Insider Transactions

No Available Data

What does Scholar Rock Holding Corp do?

Who are the key executives at Scholar Rock Holding Corp?

Clinton Bybee is the 10 percent owner of Scholar Rock Holding Corp. Other key executives at Scholar Rock Holding Corp include Chief Operating Officer Keith Woods , Chief Financial Officer Vikas Sinha , and SVP AND HEAD OF RESEARCH Mo Qatanani .

Scholar Rock Holding Corp (SRRK) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Scholar Rock Holding Corp (SRRK). Other recent insider transactions involving Scholar Rock Holding Corp (SRRK) include a net sale of 220,263 shares made by Mo Qatanani , a net sale of 11,495 shares made by Katie Peng , and a net sale of 51,716 shares made by Jeffrey S. Flier .

In summary, during the past 3 months, insiders sold 17,149 shares of Scholar Rock Holding Corp (SRRK) in total and bought 0 shares, with a net sale of 17,149 shares. During the past 18 months, 578,060 shares of Scholar Rock Holding Corp (SRRK) were sold and 530,038 shares were bought by its insiders, resulting in a net sale of 48,022 shares.

Scholar Rock Holding Corp (SRRK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Scholar Rock Holding Corp Insider Transactions

No Available Data

What does Unity Biotechnology Inc do?

Who are the key executives at Unity Biotechnology Inc?

Clinton Bybee is the 10 percent owner of Unity Biotechnology Inc. Other key executives at Unity Biotechnology Inc include director & President and Secretary Craig R. Jalbert , See Remarks Alexander Hieu Nguyen , and director & Chief Executive Officer Anirvan Ghosh .

Unity Biotechnology Inc (UNBX) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Unity Biotechnology Inc (UNBX). Other recent insider transactions involving Unity Biotechnology Inc (UNBX) include a net sale of 19,806 shares made by Alexander Hieu Nguyen , a net sale of 96,797 shares made by Anirvan Ghosh , and a net sale of 21,867 shares made by Lynne Marie Sullivan .

In summary, during the past 3 months, insiders sold 0 shares of Unity Biotechnology Inc (UNBX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 138,470 shares of Unity Biotechnology Inc (UNBX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 138,470 shares.

Unity Biotechnology Inc (UNBX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Unity Biotechnology Inc Insider Transactions

No Available Data

What does Pulmatrix Inc do?

Who are the key executives at Pulmatrix Inc?

Clinton Bybee is the other: Former 10% owner of Pulmatrix Inc. Other key executives at Pulmatrix Inc include Interim CFO Peter Ludlum , Chief Medical Officer Margaret Wasilewski , and Vice President & Finance Michelle Siegert .

Pulmatrix Inc (PULM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pulmatrix Inc (PULM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pulmatrix Inc (PULM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pulmatrix Inc (PULM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pulmatrix Inc Insider Transactions

No Available Data

What does Quanterix Corp do?

Who are the key executives at Quanterix Corp?

Clinton Bybee is the 10 percent owner of Quanterix Corp. Other key executives at Quanterix Corp include Chief Financial Officer Jason F. Faessler , Chief Commercial Officer Benjamin Meadows , and Chief Legal Officer Daniel Char .

Quanterix Corp (QTRX) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Quanterix Corp (QTRX). Other recent insider transactions involving Quanterix Corp (QTRX) include a net purchase of 370,000 shares made by David R Walt , a net purchase of 192,513 shares made by William P Donnelly , and a net purchase of 45,900 shares made by Masoud Toloue .

In summary, during the past 3 months, insiders sold 0 shares of Quanterix Corp (QTRX) in total and bought 99,400 shares, with a net purchase of 99,400 shares. During the past 18 months, 0 shares of Quanterix Corp (QTRX) were sold and 616,063 shares were bought by its insiders, resulting in a net purchase of 616,063 shares.

Quanterix Corp (QTRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Quanterix Corp Insider Transactions

No Available Data

What does Xtera Communications Inc do?

Who are the key executives at Xtera Communications Inc?

Clinton Bybee is the director & 10 percent owner of Xtera Communications Inc. Other key executives at Xtera Communications Inc include 10 percent owner Arch Venture Partners Vi Llc , 10 percent owner Keith Crandell , and 10 percent owner Robert Nelsen .

Xtera Communications Inc (XCOMQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Xtera Communications Inc (XCOMQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Xtera Communications Inc (XCOMQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Xtera Communications Inc (XCOMQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Xtera Communications Inc Insider Transactions

No Available Data

What does PhaseRx Inc do?

Who are the key executives at PhaseRx Inc?

Clinton Bybee is the 10 percent owner of PhaseRx Inc. Other key executives at PhaseRx Inc include Chief Medical Officer Gordon Brandt , director & 10 percent owner Steven Gillis , and director & 10 percent owner Brian G Atwood .

PhaseRx Inc (PZRXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of PhaseRx Inc (PZRXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhaseRx Inc (PZRXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

PhaseRx Inc (PZRXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

PhaseRx Inc Insider Transactions

No Available Data

What does Juno Therapeutics Inc do?

Who are the key executives at Juno Therapeutics Inc?

Clinton Bybee is the 10 percent owner of Juno Therapeutics Inc. Other key executives at Juno Therapeutics Inc include director & CEO & President Hans Edgar Bishop , 10 percent owner Celgene Corp /de/ , and 10 percent owner Celgene Switzerland Llc .

Juno Therapeutics Inc (JUNO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Juno Therapeutics Inc (JUNO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Juno Therapeutics Inc (JUNO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Juno Therapeutics Inc (JUNO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Juno Therapeutics Inc Insider Transactions

No Available Data

What does Adesto Technologies Corp do?

Who are the key executives at Adesto Technologies Corp?

Clinton Bybee is the 10 percent owner of Adesto Technologies Corp. Other key executives at Adesto Technologies Corp include VP & Worldwide Sales Thomas D Spade , 10 percent owner 180 Degree Capital Corp. /ny/ , and 10 percent owner Robert Nelsen .

Adesto Technologies Corp (IOTS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Adesto Technologies Corp (IOTS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Adesto Technologies Corp (IOTS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Adesto Technologies Corp (IOTS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adesto Technologies Corp Insider Transactions

No Available Data

What does Sage Therapeutics Inc do?

Who are the key executives at Sage Therapeutics Inc?

Clinton Bybee is the 10 percent owner of Sage Therapeutics Inc. Other key executives at Sage Therapeutics Inc include See Remarks Michael C. Quirk , See Remarks Gregory L. Shiferman , and director & See Remarks Jeffrey M Jonas .

Sage Therapeutics Inc (SAGE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sage Therapeutics Inc (SAGE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sage Therapeutics Inc (SAGE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sage Therapeutics Inc (SAGE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sage Therapeutics Inc Insider Transactions

No Available Data

What does Agios Pharmaceuticals Inc do?

Who are the key executives at Agios Pharmaceuticals Inc?

Clinton Bybee is the 10 percent owner of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Medical Officer Sarah Gheuens , director & Chief Executive Officer Brian Goff , and Chief Legal Officer James William Burns .

Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Agios Pharmaceuticals Inc (AGIO). Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 68,804 shares made by Sarah Gheuens , a net sale of 85,611 shares made by Brian Goff , and a net sale of 16,539 shares made by Cecilia Jones .

In summary, during the past 3 months, insiders sold 34,007 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 34,007 shares. During the past 18 months, 231,543 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 231,543 shares.

Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agios Pharmaceuticals Inc Insider Transactions

No Available Data

What does Bellerophon Therapeutics Inc do?

Who are the key executives at Bellerophon Therapeutics Inc?

Clinton Bybee is the 10 percent owner of Bellerophon Therapeutics Inc. Other key executives at Bellerophon Therapeutics Inc include 10 percent owner Puissance Life Science Opportunities Fund Vi , VP of Business Operations Parag Suresh Shah , and See Remarks Martin Dekker .

Bellerophon Therapeutics Inc (BLPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Bellerophon Therapeutics Inc (BLPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Bellerophon Therapeutics Inc (BLPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Bellerophon Therapeutics Inc (BLPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bellerophon Therapeutics Inc Insider Transactions

No Available Data

What does Achaogen Inc do?

Who are the key executives at Achaogen Inc?

Clinton Bybee is the 10 percent owner of Achaogen Inc. Other key executives at Achaogen Inc include 10 percent owner Robert W Duggan , Chief Operating Officer Elizabeth Bhatt , and See Remarks Gary Loeb .

Achaogen Inc (AKAOQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achaogen Inc (AKAOQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achaogen Inc (AKAOQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achaogen Inc (AKAOQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achaogen Inc Insider Transactions

No Available Data

What does Fate Therapeutics Inc do?

Who are the key executives at Fate Therapeutics Inc?

Clinton Bybee is the 10 percent owner of Fate Therapeutics Inc. Other key executives at Fate Therapeutics Inc include Chief Development Officer Bahram Valamehr , See Remarks Cindy Tahl , and Chief Financial Officer Kamal Adawi .

Fate Therapeutics Inc (FATE) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Fate Therapeutics Inc (FATE). Other recent insider transactions involving Fate Therapeutics Inc (FATE) include a net sale of 92,549 shares made by Bahram Valamehr , and a net sale of 84,016 shares made by Cindy Tahl .

In summary, during the past 3 months, insiders sold 82,747 shares of Fate Therapeutics Inc (FATE) in total and bought 0 shares, with a net sale of 82,747 shares. During the past 18 months, 176,565 shares of Fate Therapeutics Inc (FATE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 176,565 shares.

Fate Therapeutics Inc (FATE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Fate Therapeutics Inc Insider Transactions

No Available Data

What does bluebird bio Inc do?

Who are the key executives at bluebird bio Inc?

Clinton Bybee is the 10 percent owner of bluebird bio Inc. Other key executives at bluebird bio Inc include Chief Commercial Officer & SGD Thomas J Klima , Chief Medical Officer Richard A Colvin , and President of SGD Andrew Obenshain .

bluebird bio Inc (BLUE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of bluebird bio Inc (BLUE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of bluebird bio Inc (BLUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

bluebird bio Inc (BLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

bluebird bio Inc Insider Transactions

No Available Data

What does NeurogesX Inc do?

Who are the key executives at NeurogesX Inc?

Clinton Bybee is the 10 percent owner of NeurogesX Inc. Other key executives at NeurogesX Inc include President and CEO Ron Martell , Exec. V.P. & COO & CFO Stephen F Ghiglieri , and director & 10 percent owner Robert Nelsen .

NeurogesX Inc (NGSX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NeurogesX Inc (NGSX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NeurogesX Inc (NGSX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NeurogesX Inc (NGSX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NeurogesX Inc Insider Transactions

No Available Data

What does Bio Green Med Solution Inc do?

Who are the key executives at Bio Green Med Solution Inc?

Clinton Bybee is the 10 percent owner of Bio Green Med Solution Inc. Other key executives at Bio Green Med Solution Inc include 10 percent owner Kim Choy Yap , 10 percent owner Yee Lung Ong , and 10 percent owner Khai Loon Kua .

Bio Green Med Solution Inc (BGMS) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Bio Green Med Solution Inc (BGMS). Other recent insider transactions involving Bio Green Med Solution Inc (BGMS) include a net sale of 404,505 shares made by Kim Choy Yap , a net sale of 404,465 shares made by Khai Loon Kua , and a net sale of 277,910 shares made by Diversified Berhad Fitters .

In summary, during the past 3 months, insiders sold 0 shares of Bio Green Med Solution Inc (BGMS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,498,095 shares of Bio Green Med Solution Inc (BGMS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,498,095 shares.

Bio Green Med Solution Inc (BGMS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bio Green Med Solution Inc Insider Transactions

No Available Data

What does Alnylam Pharmaceuticals Inc do?

Who are the key executives at Alnylam Pharmaceuticals Inc?

Clinton Bybee is the 10 percent owner of Alnylam Pharmaceuticals Inc. Other key executives at Alnylam Pharmaceuticals Inc include Chief Human Resources Officer Melissa Mclaughlin , CSO & EVP & Head of Research Kevin Joseph Fitzgerald , and CMO & EVP Dev & Med Affairs Pushkal Garg .

Alnylam Pharmaceuticals Inc (ALNY) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Alnylam Pharmaceuticals Inc (ALNY). Other recent insider transactions involving Alnylam Pharmaceuticals Inc (ALNY) include a net sale of 118,757 shares made by Yvonne Greenstreet , a net sale of 35,160 shares made by Pushkal Garg , and a net sale of 13,651 shares made by Tolga Tanguler .

In summary, during the past 3 months, insiders sold 0 shares of Alnylam Pharmaceuticals Inc (ALNY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 283,451 shares of Alnylam Pharmaceuticals Inc (ALNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 283,451 shares.

Alnylam Pharmaceuticals Inc (ALNY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alnylam Pharmaceuticals Inc Insider Transactions

No Available Data

What does Illumina Inc do?

Who are the key executives at Illumina Inc?

Clinton Bybee is the 10 percent owner of Illumina Inc. Other key executives at Illumina Inc include SVP & Strategy/Corp Development Christensen Jakob Wedel , Chief Legal Officer Julie Ann Coletti , and Chief Legal Officer Scott M Davies .

Illumina Inc (ILMN) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Illumina Inc (ILMN). Other recent insider transactions involving Illumina Inc (ILMN) include a net sale of 3,059,258 shares made by Keith Meister , a net sale of 3,504 shares made by Scott M Davies , and a net sale of 3,937 shares made by Patricia Leckman .

In summary, during the past 3 months, insiders sold 2,062,465 shares of Illumina Inc (ILMN) in total and bought 0 shares, with a net sale of 2,062,465 shares. During the past 18 months, 3,070,981 shares of Illumina Inc (ILMN) were sold and 19,150 shares were bought by its insiders, resulting in a net sale of 3,051,831 shares.

Illumina Inc (ILMN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Illumina Inc Insider Transactions

No Available Data

What does 908 Devices Inc do?

Who are the key executives at 908 Devices Inc?

Clinton Bybee is the 10 percent owner of 908 Devices Inc. Other key executives at 908 Devices Inc include Chief Technology Officer Christopher D. Brown , Chief Financial Officer Griffith Joseph H. Iv , and 10 percent owner Awm Investment Company, Inc. .

908 Devices Inc (MASS) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in 908 Devices Inc (MASS). Other recent insider transactions involving 908 Devices Inc (MASS) include a net sale of 170,000 shares made by Christopher D. Brown , a net sale of 244,764 shares made by Kevin J. Knopp , and a net sale of 420,151 shares made by Awm Investment Company, Inc. .

In summary, during the past 3 months, insiders sold 459,077 shares of 908 Devices Inc (MASS) in total and bought 0 shares, with a net sale of 459,077 shares. During the past 18 months, 1,000,781 shares of 908 Devices Inc (MASS) were sold and 40,000 shares were bought by its insiders, resulting in a net sale of 960,781 shares.

908 Devices Inc (MASS)'s detailed insider trading history can be found in Insider Trading Tracker table.

908 Devices Inc Insider Transactions

No Available Data

What does Sana Biotechnology Inc do?

Who are the key executives at Sana Biotechnology Inc?

Clinton Bybee is the 10 percent owner of Sana Biotechnology Inc. Other key executives at Sana Biotechnology Inc include EVP & Chief Scientific Officer Dhavalkumar Dhirajlal Patel , EVP & Chief Financial Officer Brian Piper , and See Remarks Susan D. Wyrick .

Sana Biotechnology Inc (SANA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sana Biotechnology Inc (SANA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sana Biotechnology Inc (SANA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sana Biotechnology Inc (SANA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sana Biotechnology Inc Insider Transactions

No Available Data

What does Lyell Immunopharma Inc do?

Who are the key executives at Lyell Immunopharma Inc?

Clinton Bybee is the 10 percent owner of Lyell Immunopharma Inc. Other key executives at Lyell Immunopharma Inc include Chief Medical Officer David Shook , Chief Technical Ops. Officer Stephen J. Hill , and Chief Scientific Officer Gary K. Lee .

Lyell Immunopharma Inc (LYEL) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Lyell Immunopharma Inc (LYEL). Other recent insider transactions involving Lyell Immunopharma Inc (LYEL) include a net purchase of 148,274 shares made by Lynn Seely , a net sale of 5,394 shares made by Gary K. Lee , and a net sale of 3,796 shares made by Stephen J. Hill .

In summary, during the past 3 months, insiders sold 13,786 shares of Lyell Immunopharma Inc (LYEL) in total and bought 0 shares, with a net sale of 13,786 shares. During the past 18 months, 43,536 shares of Lyell Immunopharma Inc (LYEL) were sold and 1,012,830 shares were bought by its insiders, resulting in a net purchase of 969,294 shares.

Lyell Immunopharma Inc (LYEL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Lyell Immunopharma Inc Insider Transactions

No Available Data

What does Neumora Therapeutics Inc do?

Who are the key executives at Neumora Therapeutics Inc?

Clinton Bybee is the 10 percent owner of Neumora Therapeutics Inc. Other key executives at Neumora Therapeutics Inc include Chief Strategy Officer Daljit Singh Aurora , See Remarks Michael Lee Milligan , and Chief Financial Officer Joshua Pinto .

Neumora Therapeutics Inc (NMRA) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Neumora Therapeutics Inc (NMRA). Other recent insider transactions involving Neumora Therapeutics Inc (NMRA) include a net sale of 574,701 shares made by Daljit Singh Aurora , a net purchase of 1,915,700 shares made by Arch Venture Fund X, L.p. , and a net purchase of 1,915,700 shares made by Arch Venture Partners Xii, Llc .

In summary, during the past 3 months, insiders sold 453,833 shares of Neumora Therapeutics Inc (NMRA) in total and bought 0 shares, with a net sale of 453,833 shares. During the past 18 months, 591,923 shares of Neumora Therapeutics Inc (NMRA) were sold and 5,747,100 shares were bought by its insiders, resulting in a net purchase of 5,155,177 shares.

Neumora Therapeutics Inc (NMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neumora Therapeutics Inc Insider Transactions

No Available Data

What does Q32 Bio Inc do?

Who are the key executives at Q32 Bio Inc?

Clinton Bybee is the 10 percent owner of Q32 Bio Inc. Other key executives at Q32 Bio Inc include CFO and President Lee Kalowski , director & CEO Jodie Pope Morrison , and Chief Scientific Officer Shelia M. Violette .

Q32 Bio Inc (QTTB) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Q32 Bio Inc (QTTB). Other recent insider transactions involving Q32 Bio Inc (QTTB) include a net sale of 52,741 shares made by Jodie Pope Morrison , a net sale of 21,279 shares made by Lee Kalowski , and a net sale of 8,603 shares made by Shelia M. Violette .

In summary, during the past 3 months, insiders sold 16,615 shares of Q32 Bio Inc (QTTB) in total and bought 0 shares, with a net sale of 16,615 shares. During the past 18 months, 82,623 shares of Q32 Bio Inc (QTTB) were sold and 3,750,000 shares were bought by its insiders, resulting in a net purchase of 3,667,377 shares.

Q32 Bio Inc (QTTB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Q32 Bio Inc Insider Transactions

No Available Data

What does Boundless Bio Inc do?

Who are the key executives at Boundless Bio Inc?

Clinton Bybee is the 10 percent owner of Boundless Bio Inc. Other key executives at Boundless Bio Inc include 10 percent owner Kevin C Tang , 10 percent owner Arch Venture Fund Ix Overage, L.p. , and 10 percent owner Keith Crandell .

Boundless Bio Inc (BOLD) Insider Trades Summary

Over the past 18 months, Clinton Bybee made no insider transaction in Boundless Bio Inc (BOLD). Other recent insider transactions involving Boundless Bio Inc (BOLD) include a net purchase of 593,123 shares made by Kevin C Tang , a net sale of 16,000 shares made by Arch Venture Fund Ix Overage, L.p. , and a net sale of 16,000 shares made by Keith Crandell .

In summary, during the past 3 months, insiders sold 50,300 shares of Boundless Bio Inc (BOLD) in total and bought 611,423 shares, with a net purchase of 561,123 shares. During the past 18 months, 50,300 shares of Boundless Bio Inc (BOLD) were sold and 611,423 shares were bought by its insiders, resulting in a net purchase of 561,123 shares.

Boundless Bio Inc (BOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Boundless Bio Inc Insider Transactions

No Available Data

Clinton Bybee Mailing Address

Above is the net worth, insider trading, and ownership report for Clinton Bybee. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Clinton Bybee's mailing address is: Chicago Il 60631.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.